1-Chroman-8-yl-piperazine | 98224-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-Chroman-8-yl-piperazine
• 英文别名: 1-(Chroman-8-yl)piperazine；1-(3,4-dihydro-2H-chromen-8-yl)piperazine
• CAS: 98224-23-8
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: KHYGOQFBXDRXCE-UHFFFAOYSA-N

物化性质

• 沸点：
  397.0±42.0 °C(Predicted)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yloxy)-butyraldehyde 、 1-Chroman-8-yl-piperazine 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 7-[4-(4-chroman-8-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one
  参考文献：
  名称：

  Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder

  摘要：

  The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D-2 partial agonists is described. Our goal was to optimize the affinities for the D-2, 5-HT2A and 5-HT1A receptors, such that the D-2/5-HT2A ratio was greater than 5 to ensure maximal occupancy of these receptors when the D-2 occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED = 0.3 mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1 mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.059
• 作为产物：
  描述：

  8-溴苯并二氢吡喃 在 三(邻甲基苯基)磷 、 三氟乙酸 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 sodium t-butanolate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 1-Chroman-8-yl-piperazine
  参考文献：
  名称：

  Synthesis of arylpiperazines via palladium-catalysed aromatic amination reactions of bromoarenes with N-tert-butoxycarbonylpiperazine

  摘要：

  Reaction of a series of bicyclic bromoarenes with N-tert-butoxycarbonylpiperazine (N-Boc-piperazine) under palladium-calalysed coupling conditions followed by routine removal of the Boc group with trifluoroacetic acid in dichloromethane gave the corresponding arylpiperazines in moderate to good yield. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)00179-8

文献信息

• [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
  申请人：Clark D. Jerry

  公开号：US20050043309A1

  公开（公告）日：2005-02-24

  This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R 1 , and R 4 through R 7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

  这项发明涉及公式1的化合物 其中G、D、A、Z、Q、X、Y、R 1 和R 4 至R 7 的定义如规范中所述，制备这些化合物的方法以及用于制备这些化合物的中间体，以及含有这些化合物的药物组合物及其在治疗中枢神经系统疾病和其他疾病中的用途。
• Improvement in the Selectivity and Metabolic Stability of the Serotonin 5-HT_1A Ligand, S 15535:  A Series of <i>cis</i>- and <i>trans</i>-2-(Arylcycloalkylamine) 1-Indanols
  作者：Jean-Louis Peglion、Bertrand Goument、Nicole Despaux、Valérie Charlot、Hélène Giraud、Christian Nisole、Adrian Newman-Tancredi、Anne Dekeyne、Marc Bertrand、Patrick Genissel、Mark J. Millan

  DOI：10.1021/jm010975+

  日期：2002.1.1

  antidepressant, and procognitive properties. In an attempt to increase its selectivity and metabolic stability, and guided by the results of human metabolic studies, we prepared a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols. Irrespective of the nature of the arylcycloalkylamine moiety or the presence of substituents on the indanol ring, trans isomers invariably showed the highest affinity

  S 15535（1）在突触前和突触后5-HT（1A）受体上分别显示出激动剂和拮抗剂（弱部分激动剂）活性的独特特征。它已被证明在预测抗焦虑，抗抑郁和认知特性的几种模型中具有活性。为了提高其选择性和代谢稳定性，并以人类代谢研究的结果为指导，我们制备了一系列顺式和反式-2-（芳基环烷基胺）1-茚满醇。不论芳基环烷基胺部分的性质如何，或在茚满环上存在取代基，反式异构体始终显示出对人重组h5-HT（1A）受体的最高亲和力。其中，化合物39、42、45、49、52、53、54、57、61、64、67和70显示出与母体化合物1相似或更高的亲和力（pK（i）>或= 9.1）。5-HT（1A）配体经常遇到对α1-肾上腺素受体缺乏选择性的情况。尽管S 15535本身在这方面表现出合理的选择性（158倍），但反式哌嗪衍生物4-trans，35、39、41、47、64、68、69、70、71与alpha1-肾上腺
• Indolizines and aza-analog derivatives thereof as CNS active compounds
  申请人：SCHWARZ PHARMA AG

  公开号：EP1972628A1

  公开（公告）日：2008-09-24

  Presently disclosed are indolicine-based compounds of the general formula which have medical utility, for example as antipsychotics.

  目前披露的是具有医疗用途的通式为的基于吲哚啉的化合物，例如作为抗精神病药物。
• [EN] [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA<br/>[FR] [1,8]NAPHTYRIDIN-2-ONES ET COMPOSES APPARENTES DESTINES AU TRAITEMENT DE LA SCHIZOPHRENIE
  申请人：WARNER LAMBERT CO

  公开号：WO2005019215A1

  公开（公告）日：2005-03-03

  This invention relates to compounds of the Formula (1) wherein G, A, Z, Q, X, Y, and R1 and R2 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.

  本发明涉及式（1）的化合物，其中G，A，Z，Q，X，Y和R1和R2如规范中所定义，包含它们的制药组合物以及它们在治疗中枢神经系统和其他疾病中的应用。
• [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA
  申请人：Clark D. Jerry

  公开号：US20060287310A1

  公开（公告）日：2006-12-21

  This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R 1 , and R 4 through R 7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

  本发明涉及式1的化合物，其中G、D、A、Z、Q、X、Y、R1和R4至R7如规范中所定义，制备该化合物的过程以及用于制备该化合物的中间体，以及含有该化合物的制药组合物及其在治疗中枢神经系统疾病和其他疾病中的应用。